Table 1.
Patient and Donor Characteristics. AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; MDS: myelodisplastic syndrome; BMT: bone marrow transplantation; CR: complete response; MDR: minimal residual disease; TBI: total body irradiation; MMF: mofetil mycophenolate; CMV (Cytomegalovirus); D (donor); R (recipient). Disease risk corresponding to Center for International Blood and Marrow Transplant Research CIBMTR classification. * Two patients had an antigen disparity at DQA1; Cyclophosphamide was also given before alloPBSCT at 14.5 mg/kg on two consecutive days. ° Cyclophosphamide was also given before PBSCT at 10 mg/kg on two consecutive days. CD 34+ cell doses of cell were available for all patients; CD3+ doses only for 89% of patients.
| Patients’ and Donors’ Characteristics | Total (N = 85) |
|---|---|
| Age at transplant (years) | |
| Median | 51 y |
| Range | 19–74 |
| Sex | |
| Male | 51 (60%) |
| Female | 34 (40%) |
| Disease | |
| AML | 33 (39%) |
| AML | 25 (75%) |
| Relapsed AML | 8 (25%) |
| ALL | 14 (16%) |
| ALL | 6 (43%) |
| Relapsed ALL | 8 (57%) |
| Non-Hodgkin Lymphoma | 17 (20%) |
| Multiple Myeloma | 12 (14%) |
| MDS | 4 (5%) |
| Hodgkin Lymphoma | 3 (4%) |
| Aplastic Anemia | 1 (1%) |
| Myelofibrosis | 1 (1%) |
| Disease status at Transplant | |
| 1° CR | 40 (47%) |
| >1° CR | 22 (26%) |
| Active disease | 23 (27%) |
| CIBMTR risk group | |
| Very High | 6 (7%) |
| High | 29 (34%) |
| Intermediate | 32 (38%) |
| Low | 17 (20%) |
| Not applicable | 1 (1%) |
| Source of stem cell | |
| peripheral blood stem cell | 85 (100%) |
| Sex mismatch | |
| No | 47 (55%) |
| Yes | 38 (45%) |
| Female into male | 20 (24%) |
| Donor age, years | |
| Median | 29 y |
| Range | 16–68 |
| Source of graft | |
| sibling | 20 (24%) |
| unrelated | 65 (76%) |
| HLA match | |
| 10/10 | 47 (55%) |
| 9/10 | 23 (27%) |
| 8 */10 | 15 (18%) |
| CMV serology | |
| CMV D−R− | 2 (2%) |
| CMV D+R− | 31 (37%) |
| CMV D−R+ | 2 (2%) |
| CMV D+R+ | 50 (59%) |
| Conditioning regimen | |
| Busulfan + Cyclophosphamide | 25 (30%) |
| Thiotepa + Treosulfan | 11 (13%) |
| Fludarabine + Treosulfan + Thiotepa | 7 (8%) |
| Treosulfan + Fludarabine + Cyclophosphamide | 5 (6%) |
| Treosulfan + Cyclophosphamide | 11 (13%) |
| Melphalan + Cyclophosphamide | 5 (6%) |
| Treosulfan + Cyclophosphamide + TBI 2Gy ° | 4 (5%) |
| Melphalan + Cyclophosphamide + TBI 2Gy ° | 4 (5%) |
| Busulfane + Fludarabine | 5 (6%) |
| Fludarabine + Melphalan + TBI 2Gy ° | 3 (2%) |
| Fludarabine + Thiotepa + Cyclophosphamide | 4 (5%) |
| Cyclophosphamide + ATG + Fludarabine | 1 (1%) |
| Infused cell dose * CD34+ cell × 106/kg, | |
| Median | 7 (range 2–15) |
| CD3+ cell × 108 kg | |
| Median | 2.89 (range 1.123–10.372) |
| Total Nucleated Cells × 108/kg | |
| Median | 12.1 (range 6.9–15.739) |